Veeva Systems Inc. (VEEV) Launches eSource to Streamline Clinical Trial Data

Veeva Systems Inc. (NYSE:VEEV) made a significant announcement on January 29 when it unveiled Veeva eSource, a new application within its SiteVault platform designed to improve data accuracy and ...
Yahoo Finance

Assessing Veeva Systems (VEEV) Valuation After AI Sell‑Off And New Life Sciences Adoption News

Veeva Systems (VEEV) is drawing fresh attention after a sharp pullback in information technology stocks tied to fears of artificial intelligence disruption, even as new life sciences customers ...
Morningstar

13 of the Top 20 Biopharmas Standardize Globally on Veeva Link Key People

PLEASANTON, Calif., Feb. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 13 of the top 20 biopharmas have standardized on Veeva Link Key People to enhance customer engagement ...
Investing

Veeva Systems stock hits 52-week low at $201.51

Veeva Systems Inc Class A stock reached a 52-week low of $201.51, marking a significant point in its trading history. Over the past year, Veeva Systems has experienced a decline in its stock value, ...
Yahoo Finance

Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow

PLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva eSource, a new Veeva SiteVault application designed to significantly reduce manual clinical trial ...
Diginomica

Veeva vs Salesforce - the services questions that Life Sciences organizations need to be asking - and time is running out

As noted previously, when Veeva ended its licence agreement with Salesforce, it not only triggered a battle royale for domination of big pharma CRM, it began the first massive use case for adoption of ...
Hosted on MSN

Veeva Systems announces first-ever $2 billion share buyback

The latest announcement is out from Veeva Systems ( (VEEV)). On January 5, 2026, Veeva Systems announced that its board had authorized the company’s first-ever share repurchase program, allowing the ...
Benzinga.com

Veeva Stock Drops After Q3 Earnings, Revenue Beat Estimates

The Details: Veeva reported quarterly earnings of $2.04 per share, which beat the analyst estimate of $1.95. Quarterly revenue of $811.2 million beat the Street estimate of $792.82 million.
Seeking Alpha

Veeva Systems: Overall, A Good Q2, With Only A Few Minor Issues

Veeva Systems delivered strong Q2 results, with robust revenue growth and a fortress-like balance sheet, reinforcing its leadership in the biopharma sector. The company resolved its legal dispute with ...
FierceBiotech

IQVIA and Veeva go from adversaries to friends, ending legal spat and forming long-term pact

The yearslong legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries setting aside their differences to launch a series of clinical and commercial ...
Business Wire

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete ...